# Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR…

- Source: PR Newswire M&A
- Published: 2026-11-19T09:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/adcendo-aps-announces-phase-1-clinical-data-showing-compelling-safety--antitumor-activity-with-adce-d01-in-advanced-soft-tissue-sarcoma-in-late-breaking-oral-presentation-at-2026-eortc-nci-aacr-symposium-on-molecular-targets-and--302942421.html
- Canonical: https://groundlevelnews.com/story/adcendo-aps-announces-phase-1-clinical-data-showing-compelling-safety--296689/

30% objective response rate and an 85% disease control rate on every 2-week (Q2W) schedule; all responses ongoing at data cut-off Favorable safety and tolerability profile with very few patients needing dose reduction and no discontinuation for side effects on Q2W schedule Disease control...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
